Journal article
The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia
LM Brown, A Lonsdale, A Zhu, NM Davidson, B Schmidt, A Hawkins, E Wallach, M Martin, FM Mechinaud, SL Khaw, RC Bartolo, LEA Ludlow, J Challis, I Brooks, V Petrovic, NC Venn, R Sutton, IJ Majewski, A Oshlack, PG Ekert
Blood Advances | AMER SOC HEMATOLOGY | Published : 2020
Abstract
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, and implementation of risk-adapted therapy has been instrumental in the dramatic improvements in clinical outcomes. A key to risk-adapted therapies includes the identification of genomic features of individual tumors, including chromosome number (for hyper- and hypodiploidy) and gene fusions, notably ETV6-RUNX1, TCF3-PBX1, and BCR-ABL1 in B-cell ALL (B-ALL). RNA-sequencing (RNA-seq) of large ALL cohorts has expanded the number of recurrent gene fusions recognized as drivers in ALL, and identification of these new entities will contribute to refining ALL risk stratification. We used RNA-seq on 126 ALL patients from ou..
View full abstractGrants
Awarded by Cancer Australia
Funding Acknowledgements
The RQ-PCR testing was supported by Cancer Australia PdCCRs APP1128727 Sutton. The establishment and running of the Children's Cancer Centre Tissue Bank are made possible through the generous support of Cancer In Kids@RCH(www.cika.org.au), Leukaemia Auxiliary at RCH (LARCH), the Murdoch Children's Research Institute, and The Royal Children's Hospital Foundation. This work was supported by the Victorian Government's Operational Infrastructure Support Program; the Children's Cancer Foundation (Project 131 and 132); National Health and Medical Research Council grant 1140626; SCOR grant 7015-18 from the Lymphoma and Leukemia Society; and an Australian Government Research Training Program Scholarship (L.M.B.); and the Victorian Government's Operational Infrastructure Support Program. S.L.K. is supported by a fellowship from the Victorian Cancer Agency and I.J.M. is supported by a fellowship from the Victorian Cancer Agency and by the Felton Bequest.